US FDA’s Remote Evaluations Of Drug Manufacturing Facilities May Become Public
Executive Summary
Agency is considering posting its observations from remote assessments of facilities, assistant commissioner Miller tells annual FDLI meeting; new FDA Inspectional Activities Council will develop an action plan for the agency’s inspections program.
You may also be interested in...
Resiliency Roadmap Update: US FDA Exceeds FY 2021 Inspection Projections
While better than one its ‘best case’ scenarios, FDA has completed just 31% of 15,514 domestic surveillance inspections planned for FY 2021, applications are still being delayed, and foreign inspections have for the most part yet to be tackled.
US FDA’s Regulatory Affairs Office Building Case For More User Fee Funding
ORA represented only a small fraction of the user fee programs’ costs in recent years, but wants to show its importance to the review process.
Forty-Eight US FDA Drug Application Decisions Delayed By Pandemic's Deferred Inspections
US FDA 'resilience' report charts how inspection backlog grew and impacted approvals and compliance follow-up.